Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
6Customers
2Debt Items
7Related Chains
Source-Backed Evidence Depth
BridgeBio Oncology Therapeutics, Inc. (BBOT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
2Distinct source URLs
4High confidence
0.751Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BridgeBio Oncology Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
92%
In May 2018, the Company entered into a cooperative research and development agreement ("LLNS CRADA") with Lawrence Livermore National Security, LLC ("LLNS") to explore new knowledge therapeutics pos…
Reciprocal relationship from BBIO graph: quity financing with external investors to accelerate the development of its oncology portfolio. Upon completion of the private equity financing, the Company’…
Reciprocal relationship from BBIO graph: Reciprocal relationship from BBOT graph: de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On F…
de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On February 28, 2025, TheRas Inc. (“Legacy BBOT”), a privately held Delaware corporati…
HELIX-II-MERGER-SUB-INC
HELIX-II-MERGER-SUB-INC
62%
de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On February 28, 2025, TheRas Inc. (“Legacy BBOT”), a privately held Delaware corporati…
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
LAWRENCE-LIVERMORE-NATIONAL-SECURITY-LLC
62%
inancing activities of $0.3 million for the three months ended March 31, 2026 included $0.4 million in proceeds from option exercises, offset by $0.1 million in payments of deferred transaction costs…
LEIDOS-BIOMEDICAL-RESEARCH-INC
LEIDOS-BIOMEDICAL-RESEARCH-INC
62%
inancing activities of $0.3 million for the three months ended March 31, 2026 included $0.4 million in proceeds from option exercises, offset by $0.1 million in payments of deferred transaction costs…
TRANSACTIONS-BRIDGEBIO-PHARMA-INC
TRANSACTIONS-BRIDGEBIO-PHARMA-INC
62%
de 3-kinase (“PI3K”) malignancies. BBOT is headquartered in South San Francisco, California. de-SPAC Transaction On February 28, 2025, TheRas Inc. (“Legacy BBOT”), a privately held Delaware corporati…
BridgeBio Oncology Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BBOT-DEBT-14223
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
BBOT-DEBT
Debt stack $2.6M
90%
Market cache reports total debt of $2.6M.
BridgeBio Oncology Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BridgeBio Oncology Therapeutics, Inc..
BridgeBio Oncology Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
BBOT-OWNER-CORMORANT-ASSET-MANAGEMENT-LP
Cormorant Asset Management, LP
90%
13F overlay lists Cormorant Asset Management, LP as top holder; 67 tracked holders.
BridgeBio Oncology Therapeutics, Inc. Extended Supply Chain Network
